{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:31:37Z","timestamp":1794335497927,"version":"4.9.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Peripheral artery disease (PAD) in diabetes may lead to diabetic foot ulcer and lower-extremities amputation. Glucagon-like peptide 1 receptor agonists have proven cardiovascular benefits in trials of people with type 2 diabetes at high cardiovascular risk.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n To examine the effect of liraglutide on peripheral perfusion measured as peripheral transcutaneous oxygen pressure (TcP\n o<\/jats:sc>\n 2<\/jats:sub>\n ) in individuals with type 2 diabetes and PAD.\n <\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This open-label randomized clinical trial was conducted between February 1, 2021, and June 30, 2022, with a final follow-up on December 30, 2022, at University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy. Fifty-five individuals with type 2 diabetes, PAD, and TcP\n o<\/jats:sc>\n 2<\/jats:sub>\n between 30 and 49 mm Hg were included.\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomized to receive 1.8 mg of subcutaneous liraglutide or conventional treatment of cardiovascular risk factors (control group) for 6 months.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n Coprimary outcomes were the change from baseline of peripheral perfusion between groups and the comparison of the proportion of individuals who reached 10% increase of TcP\n o<\/jats:sc>\n 2<\/jats:sub>\n from baseline in each group.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Fifty-five participants (mean [SD] age, 67.5 [8.5] years; 43 [78%] male) were randomized (27 to the liraglutide group and 28 to the control group) and analyzed. Participants had a median (IQR) hemoglobin A\n 1c<\/jats:sub>\n level of 6.9% (6.5%-7.8%) and a mean (SD) TcP\n o<\/jats:sc>\n 2<\/jats:sub>\n of 40.3 (5.7) mm Hg. Transcutaneous P\n o<\/jats:sc>\n 2<\/jats:sub>\n increased over time in both groups, with significant differences favoring the liraglutide group after 6 months (estimated treatment difference, 11.2 mm Hg; 95% CI, 8.0-14.5 mm Hg;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). The 10% increase of TcP\n o<\/jats:sc>\n 2<\/jats:sub>\n occurred in 24 participants (89%) in the liraglutide group and 13 (46%) in the control group (relative risk, 1.91; 95% CI, 1.26-2.90;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Compared with the control group, individuals in the liraglutide group had a significant reduction of C-reactive protein (\u22120.4 mg\/dL; 95% CI, \u22120.7 to \u22120.07 mg\/dL;\n P<\/jats:italic>\n \u2009=\u2009.02), urinary albumin to creatinine ratio (\u2212119.4 mg\/g; 95% CI, \u2212195.0 to \u221243.8 mg\/g;\n P<\/jats:italic>\n \u2009=\u2009.003), and improvement of 6-minute walking distance (25.1 m; 95% CI, 21.8-28.3 m;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n In this randomized clinical trial of people with type 2 diabetes and PAD, liraglutide increased peripheral perfusion detected by TcP\n o<\/jats:sc>\n 2<\/jats:sub>\n measurement during 6 months of treatment. These results support the use of liraglutide to prevent the clinical progression of PAD in individuals with type 2 diabetes.\n <\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04881110<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.1545","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T11:08:17Z","timestamp":1710241697000},"page":"e241545","source":"Crossref","is-referenced-by-count":66,"title":["Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease"],"prefix":"10.1001","volume":"7","author":[{"given":"Paola","family":"Caruso","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ida","family":"Maiorino","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"},{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Longo","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"},{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"},{"name":"PhD Program of Translational Medicine, Department of Experimental Medicine, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Porcellini","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"},{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Matrone","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"},{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Digitale Selvaggio","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"},{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Gicchino","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Carbone","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"},{"name":"PhD Program of Translational Medicine, Department of Experimental Medicine, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Scappaticcio","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bellastella","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"},{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Giugliano","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Esposito","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"},{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"zoi240084r2","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"Cardiovascular disease and risk management: standards of care in diabetes\u20142023.","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"zoi240084r3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12933-021-01325-3","article-title":"Up and down waves of glycemic control and lower-extremity amputation in diabetes.","volume":"20","author":"Caruso","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"zoi240084r4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-018-0781-1","article-title":"Lower extremity arterial disease in patients with diabetes: a contemporary narrative review.","volume":"17","author":"Nativel","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"zoi240084r5","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.2337\/dc20-1347","article-title":"Diabetic foot problems during the COVID-19 pandemic in a tertiary care center: the emergency among the emergencies.","volume":"43","author":"Caruso","year":"2020","journal-title":"Diabetes Care"},{"issue":"9901","key":"zoi240084r6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"issue":"16","key":"zoi240084r7","doi-asserted-by":"publisher","first-page":"9801","DOI":"10.3390\/ijerph19169801","article-title":"Approaches to peripheral artery disease in diabetes: are there any differences?","volume":"19","author":"Achim","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"zoi240084r8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-6-200409210-00007","article-title":"Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.","author":"Selvin","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi240084r9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12933-021-01401-8","article-title":"Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.","volume":"20","author":"Maiorino","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"zoi240084r10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"19","key":"zoi240084r11","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi240084r12","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi240084r13","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2337\/dc18-1094","article-title":"The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial.","volume":"41","author":"Dhatariya","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"zoi240084r14","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3627","article-title":"Pleiotropic effects of GLP-1 receptor agonists on peripheral artery disease: is there any hope?","volume":"39","author":"Caruso","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"key":"zoi240084r15","doi-asserted-by":"publisher","author":"Schulz","journal-title":"BMJ","DOI":"10.1136\/bmj.c332"},{"issue":"2","key":"zoi240084r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108390","article-title":"Impact of glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: a narrative review.","volume":"37","author":"Liarakos","year":"2023","journal-title":"J Diabetes Complications"},{"issue":"4","key":"zoi240084r17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"zoi240084r18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10157","key":"zoi240084r19","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"zoi240084r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109076","article-title":"Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a retrospective multi-institutional study.","volume":"180","author":"Hsiao","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"zoi240084r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.6125","article-title":"Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes.","volume":"1","author":"O\u2019Brien","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi240084r22","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00125-021-05497-1","article-title":"Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors.","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"issue":"7","key":"zoi240084r23","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1111\/dom.14361","article-title":"Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: a real-world study in two Italian cohorts.","volume":"23","author":"Baviera","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"zoi240084r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101325","article-title":"Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?","volume":"48","author":"Scheen","year":"2022","journal-title":"Diabetes Metab"},{"issue":"11","key":"zoi240084r25","doi-asserted-by":"publisher","first-page":"E947","DOI":"10.1152\/ajpendo.00400.2015","article-title":"Exenatide exerts direct protective effects on endothelial cells through the AMPK\/Akt\/eNOS pathway in a GLP-1 receptor-dependent manner.","volume":"310","author":"Wei","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"zoi240084r26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"zoi240084r27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1475-2840-13-49","article-title":"Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.","volume":"13","author":"Rizzo","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"zoi240084r28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/1479164113481817","article-title":"The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-\/-) mouse model.","volume":"10","author":"Gaspari","year":"2013","journal-title":"Diab Vasc Dis Res"},{"issue":"4","key":"zoi240084r29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00125-013-3145-0","article-title":"Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.","volume":"57","author":"Hogan","year":"2014","journal-title":"Diabetologia"},{"issue":"6","key":"zoi240084r30","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/dom.14343","article-title":"Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: analyses from the LYDIA trial.","volume":"23","author":"Ahmad","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"zoi240084r31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13047-020-00383-2","article-title":"Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer.","volume":"13","author":"Armstrong","year":"2020","journal-title":"J Foot Ankle Res"},{"key":"zoi240084r1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2021","edition":"10th ed"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2815948\/caruso_2024_oi_240084_1762537960.91758.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T16:01:47Z","timestamp":1762963307000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2815948"}},"subtitle":["The STARDUST Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.1545","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]}}}